The present invention relates to variants of
interleukin-2 (IL2). In one embodiment, the IL2 variant activates
effector T cells in preference to regulatory T cells. In particular, the present invention relates to polypeptides comprising
mutant proteins of human IL2 or
mutant proteins of human IL2 functional variants, wherein human IL2 or its functional variants are at least replaced at positions of acidic or basic
amino acid residues contacting the α
subunit of the αβγIL2
receptor complex (I12Kαβγ) in wild-type human IL2. Alternatively, the
mutant proteins of human IL2 or mutant proteins of human IL2 functional variants include at least (i) one or more
amino acid replacements that reduce affinity for the α
subunit of II_2Kαβγ, and (ii) one or more
amino acid replacements that enhance affinity for II_2Kβγ. The present invention also relates to polynucleotides encoding the polypeptides of the present invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or preventive methods for treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions, and pharmaceutical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.